SenesTech Appoints Joe Malinowski as Vice President of Sales

FLAGSTAFF, Ariz., Feb. 5, 2018 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the developer of ContraPest®, a paradigm shifting technology that focuses on rodent management through fertility control, announced today the appointment of Mr. Joe Malinowski as Vice President of Sales effective February 1, 2018.

SenesTech, Inc. has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company's first fertility control product, ContraPest(R), is marketed for use initially in controlling rat infestations.

Mr. Malinowski joins SenesTech with more than 30 years of experience in the national pest control industry. His industry background includes significant management and operating experience at industry leaders including Terminix, and specifically, Orkin, where he served from 1979 to 2002, in positions of increasing levels of responsibilities during his tenure.

Dr. Loretta Mayer, chairman and chief executive officer of SenesTech, said, "I am pleased to have an industry executive the caliber of Joe Malinowski join SenesTech at this important point in the history of the Company. His broad industry expertise, as well as contacts throughout the industry, will be instrumental to SenesTech as we work to establish ContraPest® as one of the most effective solutions in the pest control industry."

Mr. Malinowski said, "I see a great opportunity with a unique solution that can achieve breakthrough results. The demand for effective pest management continues unabated as it has for centuries. I believe ContraPest® offers a sustainable solution that traditional poison baits have not been able to produce. I look forward toward working with the entire SenesTech team to develop this opportunity."

About SenesTech 

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

ContraPest®'s innnovative technology and approach targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly. In contrast, the historical approach to managing rat pest populations, poison bait blocks, carries a high risk of environmental contamination and the poisoning of non-target animals, pets, and children. ContraPest® is a Restricted Use product.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in improved performance in rodent control over poison options, without the negative environmental effects. For more information visit the SenesTech website at

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

SOURCE SenesTech, Inc.

For further information: Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700,; Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143